Back to Search Start Over

From single drug targets to synergistic network pharmacology in ischemic stroke.

Authors :
Casas AI
Hassan AA
Larsen SJ
Gomez-Rangel V
Elbatreek M
Kleikers PWM
Guney E
Egea J
López MG
Baumbach J
Schmidt HHHW
Source :
Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2019 Apr 02; Vol. 116 (14), pp. 7129-7136. Date of Electronic Publication: 2019 Mar 20.
Publication Year :
2019

Abstract

Drug discovery faces an efficacy crisis to which ineffective mainly single-target and symptom-based rather than mechanistic approaches have contributed. We here explore a mechanism-based disease definition for network pharmacology. Beginning with a primary causal target, we extend this to a second using guilt-by-association analysis. We then validate our prediction and explore synergy using both cellular in vitro and mouse in vivo models. As a disease model we chose ischemic stroke, one of the highest unmet medical need indications in medicine, and reactive oxygen species forming NADPH oxidase type 4 ( Nox4 ) as a primary causal therapeutic target. For network analysis, we use classical protein-protein interactions but also metabolite-dependent interactions. Based on this protein-metabolite network, we conduct a gene ontology-based semantic similarity ranking to find suitable synergistic cotargets for network pharmacology. We identify the nitric oxide synthase ( Nos1 to 3 ) gene family as the closest target to Nox4 Indeed, when combining a NOS and a NOX inhibitor at subthreshold concentrations, we observe pharmacological synergy as evidenced by reduced cell death, reduced infarct size, stabilized blood-brain barrier, reduced reoxygenation-induced leakage, and preserved neuromotor function, all in a supraadditive manner. Thus, protein-metabolite network analysis, for example guilt by association, can predict and pair synergistic mechanistic disease targets for systems medicine-driven network pharmacology. Such approaches may in the future reduce the risk of failure in single-target and symptom-based drug discovery and therapy.<br />Competing Interests: Conflict of interest statement: H.H.H.W.S. is a cofounder of a biotech company, Vasopharm, engaged in the development of small-molecule NOS inhibitors, currently in stage III clinical development. However, H.H.H.W.S. has no operative role in the company and holds less than 1% of shares.<br /> (Copyright © 2019 the Author(s). Published by PNAS.)

Details

Language :
English
ISSN :
1091-6490
Volume :
116
Issue :
14
Database :
MEDLINE
Journal :
Proceedings of the National Academy of Sciences of the United States of America
Publication Type :
Academic Journal
Accession number :
30894481
Full Text :
https://doi.org/10.1073/pnas.1820799116